Comparison between the thoracoabdominal rebalancing (TAR) method and the slow expiratory flow acceleration (SEFA) technique in preterm newborns: protocol for a randomised controlled clinical trial Authors: Gaby Kelly Bezerra de Macedo, Mayara Fabiana Pereira Costa, Luiza Gabriela de Araujo Fonseca, Sabrinne Suelen Santos Sampaio, Karolinne Souza Monteiro Published: 2026 ABSTRACT AbstractIntroductionPreterm newborns (PTNB) present respiratory immaturity and increased susceptibility to muscle fatigue. The thoracoabdominal rebalancing (TAR) method is a physiotherapeutic intervention developed in Brazil that aims to reorganise the synergy of the thoracoabdominal muscles and reduce the effort of the respiratory muscles, a benefit that is particularly important for PTNB; however, the evidence regarding its effectiveness in this population remains inconclusive. Therefore, this study aims to compare the short-term effects of the TAR method and the slow expiratory flow acceleration (SEFA) technique in improving respiratory distress and peripheral oxygen saturation (SpO2) in PTNB admitted to neonatal intensive care unit (NICU).Methods and analysisThe study will be a randomised, controlled, two-arm, parallel-group, single-blind clinical trial. 68 participants will be randomly assigned to one of the two treatment groups. Group 1 will receive four handling techniques of the TAR method for 10 min, followed by the rhinopharyngeal retrograde clearance with saline instillation (RRC+I) technique. Group 2 will receive the SEFA technique for 10 min, also followed by RRC+I. Primary outcomes are respiratory distress and SpO2. Secondary outcomes are respiratory rate (RR), heart rate (HR), pain, behaviour and diaphragmatic excursion. Assessments will be conducted by a blinded researcher at baseline (T0), immediately after the intervention (T1) and at the 30-minute follow-up (T2). Data will be described using measures of central tendency and dispersion and absolute and relative frequencies. An intention-to-treat analysis will be performed, and intragroup and intergroup comparisons will be assessed using generalised estimating equations (GEE).Ethics and disseminationThe Research Ethics Committee of the Faculty of Health Sciences of Trairi of the Federal University of Rio Grande do Norte approved this study (number 8,055,786). The results will be disseminated through peer-reviewed journal publications, scientific conferences presentations and knowledge translation to the public.Trial registration numberThis study was registered on Brazilian Registry of Clinical Trials (ReBEC) on 9 January 2026 (RBR-3gbsyc2).Keywords: Physical Therapy Modalities, Respiratory Therapy, Neonatal intensive & critical care, Infant STRENGTHS AND LIMITATIONS OF THIS STUDY This study has a robust methodological design and was reported in accordance with the recognised guidelines (Standard Protocol Items: Recommendations for Interventional Trials and Template for Intervention Description and Replication). This study has a robust methodological design and was reported in accordance with the recognised guidelines (Standard Protocol Items: Recommendations for Interventional Trials and Template for Intervention Description and Replication). The protocol provides a detailed description of all techniques, assessment methods and study procedures, thereby enhancing clinical and scientific reproducibility. The protocol provides a detailed description of all techniques, assessment methods and study procedures, thereby enhancing clinical and scientific reproducibility. Relevant respiratory outcomes for newborns will be evaluated, including diaphragmatic excursion. Relevant respiratory outcomes for newborns will be evaluated, including diaphragmatic excursion. This is a clinical trial designed to evaluate the immediate effects of the interventions, which precludes conclusions regarding sustained medium-term and long-term benefits. This is a clinical trial designed to evaluate the immediate effects of the interventions, which precludes conclusions regarding sustained medium-term and long-term benefits. Introduction Preterm birth is one of the leading causes of mortality in children younger than 5 years worldwide and represents a major challenge for health systems.1 Estimates indicate a global prevalence of 9.9% of preterm births in 2020, corresponding to approximately 13.4 million newborns.2 In addition to mortality, preterm newborns (PTNB) are at increased risk of developing acute complications, such as respiratory distress syndrome, necrotising enterocolitis, neonatal sepsis and intraventricular haemorrhage, as well as long-term morbidities, including bronchopulmonary dysplasia and periventricular leucomalacia.3 The respiratory system is one of the most affected in PTNB due to its structural and functional immaturity. The lungs of newborns have a reduced gas exchange surface area and low compliance, while the chest wall is highly compliant and the ribs are cartilaginous and horizontally oriented.4 These characteristics result in lower respiratory efficiency, as the chest wall has a reduced ability to maintain stability and prevent distortion during inspiratory efforts.5 In addition, the neonatal diaphragm appears flattened and has lower oxidative capacity, which reduces its contractile efficiency and makes it less resistant to fatigue.6 Taken together, these factors result in mechanical disadvantages and, when the work of breathing (WoB) increases, PTNB become more susceptible to respiratory muscle fatigue.7 Respiratory physiotherapy plays an important role in the management of PTNB, acting to facilitate mucociliary clearance, optimise the ventilation-perfusion relationship and improve respiratory function.8 Physiotherapeutic intervention in the neonatal intensive care unit (NICU) often includes airway clearance techniques (conventional and non-conventional), postural adjustments, ventilatory support care and sensorimotor stimulation.9 10 Among the resources, slow expiratory flow acceleration (SEFA) is considered a non-conventional technique that has demonstrated benefits for the respiratory function of PTNB.8 SEFA promotes the mobilisation of secretions from the medium-calibre airways to the proximal airways11 and is considered safe for this population.12 In addition, rhinopharyngeal retrograde clearance (RRC, or RRC+I when used with saline instillation) is a respiratory physiotherapy technique described by Postiaux13 and often used in infants to improve upper airway patency, being a more efficient alternative compared with nasopharyngeal aspiration.14 The thoracoabdominal rebalancing (TAR) is a respiratory physiotherapy method developed in the 1980s in Brazil and is applied by Brazilian physiotherapists in neonates admitted to NICUs. The TAR method proposes a global approach to the respiratory system, considering the intrinsic relationship between the lungs and the respiratory musculature.15 This intervention aims to stimulate pulmonary ventilation, promote the removal of pulmonary secretions and reorganise the thoracoabdominal muscle synergy that is disrupted in the presence of pulmonary dysfunctions, thereby improving the zone of apposition between the diaphragm and the rib cage and reducing respiratory muscle effort. This method is applied through a variety of handling techniques, including stretching, postural adjustments, myofascial manoeuvres and manual support.16 Given the specific characteristics of the respiratory system of PTNB,5–7 the TAR method represents a promising intervention for this population. While SEFA is considered a safe respiratory physiotherapy technique that promotes secretion clearance and improves peripheral oxygen saturation (SpO2) in PTNB,12 17 the benefits of the TAR method remain inconclusive. Some clinical trials have reported positive effects of TAR on increasing SpO218 19 and reducing respiratory distress.20 21 However, other studies have not demonstrated similar benefits in this population.22 23 In addition, the available studies present methodological limitations (eg, lack of assessor blinding, absence of sample size calculation, risk of selective reporting of data and absence of intention-to-treat analysis), thereby limiting confidence in their findings. Therefore, further well-designed studies are needed to determine the efficacy and safety of the TAR method in PTNB. Therefore, the aim of this study will be to compare the short-term effects of the TAR method and SEFA in improving respiratory distress and SpO2 in PTNB admitted to the NICU. As secondary objectives, we aim to analyse the impacts on heart rate (HR), respiratory rate (RR), pain, behaviour and diaphragmatic excursion. The study hypothesis is that the TAR method will lead to improvements in respiratory parameters in PTNB, particularly about respiratory distress, SpO2, RR and diaphragmatic excursion. Regarding the remaining variables, we hypothesise that the TAR method will not adversely affect HR, pain or behaviour. Methods and analysis Study design This is a protocol for a randomised, controlled, two-arm, parallel-group, single-blind clinical trial. This protocol is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines,24 and the trial findings will be reported in accordance with the CONSORT (CONsolidated Standards Of Reporting Trials) Statement.25 This clinical trial was registered on Brazilian Registry of Clinical Trials (ReBEC) on 9 January 2026 (RBR-3gbsyc2). Research location The study will be conducted in the NICU of the Ana Bezerra University Hospital, affiliated with the Federal University of Rio Grande do Norte (Santa Cruz, Rio Grande do Norte, Brazil). Data collection is scheduled to begin in August 2026 and to be completed in July 2027. Participants The study sample will consist of PTNB of both sexes who are admitted to the NICU. Eligibility criteria Newborns meeting the following criteria will be included: Gestational age <37 weeks. Gestational age <37 weeks. Chronological age >96 hours of life, in accordance with the institution’s minimal handling protocol. Chronological age >96 hours of life, in accordance with the institution’s minimal handling protocol. Use of non-invasive ventilation (NIV), including continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Use of non-invasive ventilation (NIV), including continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Silverman-Andersen Score >0. Silverman-Andersen Score >0. Newborns presenting any of the following conditions will be excluded: Haemodynamic instability (persistent hypotension, bradycardia or tachycardia, as described by Tewari et al).26 Haemodynamic instability (persistent hypotension, bradycardia or tachycardia, as described by Tewari et al).26 Use of invasive mechanical ventilation (IMV). Use of invasive mechanical ventilation (IMV). Clinical diagnosis of pneumothorax, pleural effusion, atelectasis, anaemia or congenital malformations of the chest wall, diaphragm or upper airways. Clinical diagnosis of pneumothorax, pleural effusion, atelectasis, anaemia or congenital malformations of the chest wall, diaphragm or upper airways. Cardiovascular malformations. Cardiovascular malformations. Diagnosed genetic syndromes. Diagnosed genetic syndromes. Recruitment and screening Recruitment will be conducted through active search of records of newborns admitted to the hospital’s NICU. In addition, the study will be presented to the unit’s multidisciplinary healthcare team to assist in identifying potential participants. Once eligible participants are identified, an initial contact will be made with the newborns’ legal guardians to inform them about the study objectives and procedures and to assess their interest in participation. Written informed consent will be obtained from the parents or legal guardians before any study procedures are performed. A copy of the informed consent form is provided in online supplemental appendix 1. Participant screening will initially be conducted based on information obtained from the newborn’s electronic medical records, following authorisation from the legal guardians through the signing of an informed consent form. Gestational and chronological age will be evaluated, as well as associated clinical diagnoses, in order to identify conditions that may preclude participant inclusion. Subsequently, a brief bedside assessment of the newborn will be performed to evaluate the current clinical status and the type of ventilatory support in use at the time. Parameters such as HR and blood pressure will be analysed to assess haemodynamic stability. Finally, the Silverman-Andersen Score will be applied to identify signs of respiratory distress. Randomisation and allocation Newborns will be randomly allocated into two groups: G1 (TAR and RRC+I) and G2 (SEFA and RRC+I). Randomisation will be performed using a computerised random sequence generated via the website www.sealedenvelope.com, ensuring that participants have an equal probability of being assigned to either group. Block randomisation stratified by gestational age (PTNB <28 weeks and ≥28 weeks) will be used, with a 1:1 allocation ratio between groups. This procedure will be conducted by an independent researcher who is not involved in the study. Allocation concealment will be ensured using individually opaque, sealed and sequentially numbered envelopes. The envelopes will be opened by the researcher responsible for delivering the intervention immediately prior to its administration, according to participant enrolment in the study. Blinding Participant assessments will be performed by a researcher blinded to group allocation (researcher 1). After the initial assessment, researcher 1 will leave the NICU to maintain blinding, and the physiotherapist responsible for delivering the intervention (researcher 2) will enter to deliver the intervention according to the group to which the participant has been allocated. This professional will be blinded to outcome assessments. Subsequently, researcher 2 will leave the NICU, and researcher 1 will return to repeat the assessment performed prior to the intervention. Data analysis will be conducted by a professional not involved in the previous stages of the study, who will also be blinded to group allocation (researcher 3). Intervention The intervention protocol follows the Template for Intervention Description and Replication (TIDieR) guidelines27 and will be performed at least 1 hour after the infant’s last feeding to prevent regurgitation. The professionals responsible for the intervention will be physiotherapists specialised in neonatal intensive care, with extensive experience in the field. These professionals are certified to perform the TAR method and will receive prior training regarding the TAR handling techniques to be used in this study. The training will be conducted by a physiotherapist certified in the TAR method and not involved in the research procedures. Group 1 (G1) Group 1 will receive four handling techniques of the TAR method, which will be performed over a 10-minute period. Details of the handling techniques have been described by Lima and Silva16 and are presented in table 1. Newborns will wear only a diaper and will be comfortably positioned in the supine position in the incubator with the head of the bed elevated to 30°, and rolls will be placed under the scapular region and below the knees to maintain the physiological flexor pattern (including hip flexion). The environment surrounding the incubator will be adjusted to ensure appropriate noise and lighting conditions.16 Table 1Description of the TAR handling techniques performed in this studyHandling techniqueDescriptionInspiratory assistanceElevation of the chest during inspiration, following the respiratory rhythm and applying traction to the ribs and/or sternum in the direction of thoracic cage elevation.Stretching of accessory inspiratory musclesStretching of the sternocleidomastoid, scalene, pectoral and trapezius muscles. Stretching will be performed during the expiratory phase and maintained for 30 s for each muscle.Lower abdominal supportManual pressure is applied to the lower abdomen during inspiration. In the expiratory phase, the pressure is maintained and the lower abdominal muscles are tractioned in a cranial direction, increasing diaphragmatic stretching and promoting pelvic retroversion.Ileocostal space supportApplication of gentle pressure to the ileocostal space during both the inspiratory and expiratory phases, directed from the lateral abdomen toward the umbilical region.TAR, thoracoabdominal rebalancing. Description of the TAR handling techniques performed in this study TAR, thoracoabdominal rebalancing. The RRC+I will subsequently be performed to remove secretions mobilised after the TAR method. This technique was described by Postiaux13 and consists of a forced inspiratory manoeuvre performed in infants to clear the nasopharynx. Newborns will be comfortably positioned in the supine position in the incubator with the head of the bed elevated to 30°, and rolls will be placed under the scapular region and below the knees. The physiotherapist will instil saline solution (0.9% sodium chloride) using a 1-mL syringe, followed by gentle nasal massage for a few seconds. At the end of the expiratory phase, the oral cavity is occluded and the mandible is elevated to induce a deep nasal inspiration. This manoeuvre promotes the transport of secretions to the nasopharynx, which can then be eliminated by coughing or swallowing.13 To maintain infant comfort and organisation, the four-handed containment technique (manual containment by two professionals) will be applied during the RRC+I. Group 2 (G2) Participants in G2 will receive the SEFA technique for 10 min or until secretions are mobilised. This technique uses slow expirations with low airflow and low lung volumes, facilitating the removal of secretions from the small bronchi toward the proximal airways. In this study, the technique adapted for preterm infants will be used to avoid any increase in intracranial pressure.28 The physiotherapist places one hand on the chest, between the sternal notch and the xiphoid process, while the other hand is positioned on the lower ribs without applying pressure, forming a ‘bridge’ supported by the thumb and index finger. Subsequently, gentle pressure is applied to the chest wall in the anteroposterior and cephalocaudal directions, gradually increasing expiratory flow while maintaining support on the lower ribs (this approach helps prevent contact with the abdomen and limits lower rib expansion, allowing better diaphragmatic excursion and avoiding increased intra-abdominal pressure). The manoeuvre begins at the end of the inspiratory phase and continues throughout the expiratory phase.28 Infant positioning during the SEFA and environmental adjustments will be the same as those described for Group 1. Following SEFA, the RRC+I will be performed according to the procedures previously described. Each participant will undergo only one intervention session and, after participation in the study, will continue with the usual physiotherapy treatment provided at the institution. During the study period, all medications previously prescribed for continuous infusion will be maintained, and the assessment and intervention procedures will be scheduled at times that do not coincide with nursing care activities (such as vital sign assessments and diaper changes). All newborns will be continuously monitored using pulse oximetry with a multiparametric monitor (Dixtal DX2021). In the event of any intercurrence (such as SpO2 <80%, apnoea, cyanosis or bradycardia), the intervention will be immediately discontinued, and the necessary supportive measures will be implemented to restore the participant’s clinical stability. Outcome measures Outcome assessment will follow the recommendations of the CONSORT-Outcomes 2022 Extension29 and will be performed by a blinded researcher. Outcomes will be assessed at three time points: before the intervention (T0), immediately after the intervention (T1) and at the 30-minute follow-up (T2). During assessments, newborns will wear only a diaper and will be comfortably positioned in the supine position in the incubator with the head of the bed elevated to 30°, maintaining the head in the midline and the physiological flexor pattern of the limbs with the aid of positioning rolls. Primary outcomes Respiratory distress The Silverman-Andersen Score will be used to assess respiratory distress. It is a widely used clinical tool to quantify the degree of respiratory distress in newborns by considering five parameters: intercostal retractions (upper and lower), xiphoid retraction, nasal flaring and expiratory grunting. Each item is scored from 0 to 2, yielding a total score ranging from 0 (no respiratory distress) to 10 (maximum respiratory distress).30 The Silverman-Andersen Score has demonstrated good intra-rater reliability, with an intraclass correlation coefficient (ICC) of 0.77 (95% CI 0.68 to 0.84).31 Peripheral oxygen saturation (SpO2) SpO2 will be assessed using pulse oximetry with a multiparametric monitor (Dixtal DX2021) available at the bedside in the NICU. Secondary outcomes Heart rate (HR) The multiparametric monitor (Dixtal DX2021) will be used to assess participants’ HR. Respiratory rate (RR) RR will be assessed by visually counting respiratory movements over a 1-minute period. To reduce potential measurement bias, concurrent auscultation using a stethoscope (Littmann Classic III) will be performed.32 Pain The Neonatal Infant Pain Scale (NIPS) will be used to assess pain. This is a scale validated for the Brazilian population that evaluates five behavioural factors (facial expression, crying, arm position, leg position and state of arousal) and one physiological factor (breathing pattern). Each item is scored as 0 or 1, except for crying, which is scored on a scale from 0 to 2. The total score ranges from 0 to 7, with scores greater than 3 indicating the presence of pain. The NIPS has demonstrated satisfactory inter-observer and intra-observer reliability, as well as adequate internal consistency, with a Cronbach’s alpha of 0.762.33 Behaviour Behaviour will be assessed categorically, considering aspects of the sleep-wake cycle. Newborns will be classified into three levels: sleeping/drowsy, awake/alert or irritable/crying. Diaphragmatic excursion Diaphragmatic excursion will be assessed using ultrasonography. The SonoSite M-Turbo system (Bothell, WA, USA) will be used. A convex transducer will be oriented medially in a cephalad direction, maintaining the ultrasound beam perpendicular to the posterior third of the right hemidiaphragm in the subcostal region. B-mode imaging will be used to obtain optimal visualisation of the diaphragm, with the liver serving as an acoustic window on the right to select the exploration line. M-mode will be used to measure the craniocaudal amplitude of diaphragmatic excursion during inspiration and expiration.34 The values from three consecutive respiratory cycles will be measured and recorded in centimetres (cm), and the mean of these values will be used for analysis.35 Table 2 provides further details on outcome assessment, including the tests used, analysis metrics, methods of aggregation and assessment time points for each outcome.24 29 The minimal important change (MIC) of the instruments used in this study has not yet been described in literature with respect to the preterm population. Table 2Details of the study outcome assessmentMeasurement variableTest/toolAnalysis metricMethod of aggregationTime point Primary outcomes Respiratory distressSilverman-Andersen ScoreFinal valueMean and SDT0T1T2Peripheral oxygen saturationMultiparametric monitorFinal valueMean and SDT0T1T2 Secondary outcomes Heart rateMultiparametric monitorFinal valueMean and SDT0T1T2Respiratory rateCounting of respiratory movementsFinal valueMean and SDT0T1T2PainNeonatal Infant Pain ScaleFinal valueMean and SDT0T1T2BehaviourAssessment of the sleep-wake cycleFinal valueProportion of participants (%)T0T1T2Diaphragmatic excursionUltrasonographyFinal valueMean and SDT0T1T2T0, before the intervention; T1, immediately after the intervention; T2, 30 min follow-up. Details of the study outcome assessment T0, before the intervention; T1, immediately after the intervention; T2, 30 min follow-up. Adverse events An assessment of adverse events will be conducted through continuous monitoring of the newborn’s clinical signs. HR, SpO2, respiratory pattern and skin colour will be continuously assessed by the researcher responsible for the intervention, aiming to identify the occurrence of severe bradycardia (HR <60 bpm), important desaturation (SpO2 <80%), apnoea and cyanosis. Serious adverse events will be reported based on the study by Di Polito et al36 and will include any episode that compromises the newborn’s clinical and/or haemodynamic stability, triggering a life-threatening condition or resulting in death. These events will be reviewed by the entire research team to determine whether they are attributable to the study intervention and will be reported to the Ethics Committee. Study procedures The procedures to be performed in the study are outlined in figure 1. Demographic and clinical information will be obtained to assess eligibility and to characterise participants at baseline (T0). Data will include neonatal personal information (such as date of birth, gestational age, chronological and corrected age, sex and weight), the diagnosis or health condition leading to hospital admission, APGAR, need for resuscitation and/or previous intubation, use of surfactant, current medications, associated comorbidities, duration of ventilatory support and detailed ventilatory parameters. Data will be recorded in a study-specific data collection form with access restricted to the study researchers, in order to ensure data security and confidentiality. Flowchart illustrating the stages of the study protocol. HR, heart rate; RR, respiratory rate; RRC+I, rhinopharyngeal retrograde clearance with saline instillation; SEFA, slow expiratory flow acceleration; SpO2, peripheral oxygen saturation; TAR, thoracoabdominal rebalancing. Primary outcomes (respiratory distress and SpO2) and secondary outcomes (HR, RR, pain, behaviour and diaphragmatic excursion) will be assessed at baseline (T0). After the assessments, participants will then be allocated to one of the study groups through prior randomisation, and the intervention will be administered. All outcomes will be reassessed immediately after the intervention (T1) and at the 30-minute follow-up (T2). The schedule of enrolment, interventions and assessments is presented in figure 2. SPIRIT schedule of enrolment, interventions and assessments. 0, baseline; t1, intervention time; t2, immediately after the intervention; t3, follow up; RRC+I, rhinopharyngeal retrograde clearance with saline instillation; SEFA, slow expiratory flow acceleration; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; TAR, thoracoabdominal rebalancing. Statistical analysis Sample size calculation The sample size was estimated considering the Silverman-Andersen Score as the primary outcome. The primary hypothesis concerns the difference in the trajectory of respiratory distress between the intervention and control groups over time (group-by-time interaction), which will be analysed using linear mixed-effects models. Sample size estimation was performed in R using the powerlmm package. The calculation assumed a two-sided significance level of 5%, statistical power of 80%, three repeated assessments and an expected within-subject correlation of 0.50. Because no minimal clinically important difference has been established for the Silverman-Andersen Score and the only previous randomised controlled trial did not demonstrate the effect size assumed in its original sample size calculation,22 the present study adopted a more conservative planning assumption, considering a between-group difference of 0.5 points with an SD of 0.80 (standardised effect size, Cohen’s d=0.625). This approach was chosen to reduce the risk of an underpowered study if the true treatment effect is smaller than originally anticipated. Allowing for an anticipated 10% attrition rate, a total sample of 68 newborns (34 per group) will be recruited. Data analysis Data will be tabulated and analysed using SPSS software (version 20.0). The analysis will be conducted by a blind investigator who is not involved in the recruitment, assessment or intervention phases of the study. Descriptive results will be presented as means and SD for continuous variables and as absolute and relative frequencies for categorical variables. Data normality will be assessed using the Kolmogorov-Smirnov test. Intragroup and intergroup comparisons will be analysed using the generalised estimating equations (GEE). Statistical significance will be considered at p<0.05 with a 95% CI. All participants will be analysed according to the intention-to-treat principle and data imputation will be applied for losses of less than 15%, assuming data are completely at random. Missing data will be imputed using the expectation maximisation or multiple imputation methods. Patient and public involvement Patients and members of the public (ie, a mother of a PTNB admitted to the NICU and a healthcare professional working in a NICU) were involved in the planning stage of this study, assisting in the identification of relevant outcomes from the perspective of lived experience. Additionally, the researchers intend to involve patients and the public in the dissemination of this study’s findings, as their perspectives may enhance the relevance and applicability of the results, as well as facilitate knowledge dissemination. Ethics and dissemination The study was approved by the Research Ethics Committee of the Faculty of Health Sciences of Trairi, of the Federal University of Rio Grande do Norte (approval number 8,055,786). The study will be conducted in accordance with the Declaration of Helsinki and Resolution No. 466/12 of the Brazilian National Health Council, which regulates research involving human subjects. To authorise the participation of the newborns in the study, their legal guardians will be required to sign a written informed consent form (online supplemental appendix 1). A specific consent form for image recording will be signed by the parents or legal guardians before any images are recorded. The recorded images will consist of photographs of the newborns obtained at four predefined time points: (1) baseline, (2) during the intervention, (3) immediately after the intervention and (4) the 30-minute follow-up. The photographs will be used exclusively for research documentation, to document the implementation of the intervention protocol for study quality control and to illustrate scientific publications. All images will be stored securely, handled confidentially and presented in a manner that fully preserves participant anonymity. All participant information will be kept confidential and securely protected, with access restricted by password to the researchers directly involved in data collection and analysis. Physical records will be stored in a secure location (a designated folder kept in a locked cabinet accessible only to the research team). Electronic records will be stored on a password-protected computer without internet access, accessible only to authorised members of the research team. No data will be stored on virtual platforms, shared environments or cloud-based services, in order to minimise the risk of data breaches. The results of this study will be communicated to the scientific community through publication in peer-reviewed journals and presentation at national and international conferences, thereby supporting the advancement of knowledge in this area. Furthermore, the findings will be disseminated to the broader public through knowledge translation strategies, including the use of social media platforms, with the aim of increasing awareness and informing clinical practice. Discussion This manuscript describes a protocol for a randomised controlled trial that aims to evaluate the effects of the TAR method on respiratory distress and SpO2 in PTNB admitted to the NICU. The TAR method is an intervention focused on reorganising the respiratory muscle synergy, facilitating diaphragmatic function and promoting a better balance between the thorax and abdomen.15 Therefore, if this intervention elicits positive effects, it may impact the reduction of respiratory distress in PTNB. Moreover, the expected immediate effects on SpO2 and RR may promote greater short-term clinical stability of the newborn, a benefit that is highly relevant to neonatal care. Finally, the results of this study may provide higher-quality evidence on the TAR method, especially for Brazilian NICUs and similar settings, supporting evidence-based respiratory physiotherapy. This study has a robust methodological design and was reported in accordance with the recognised guidelines (SPIRIT and TIDieR), with prospective registration to increase transparency and reduce publication bias. Stratified randomisation by gestational age will ensure group balance, particularly for extremely preterm infants. Assessor blinding and intention-to-treat analysis will be applied to minimise bias and strengthen internal validity. Additionally, this study will assess relevant respiratory outcomes, including diaphragmatic excursion, not previously investigated in clinical trials. This study has some limitations. It is a clinical trial designed to evaluate the immediate effects of the TAR method, which precludes conclusions regarding sustained medium-term and long-term benefits. Blinding of the intervention provider is not feasible, which may introduce bias. Furthermore, as a single-centre study in a small NICU, generalisability may be limited. Supplementary material Acknowledgements We would like to thank the institutions involved for the institutional and scientific support that made the development of this protocol possible. We also thank the patient and public representatives who contributed to the planning of this clinical trial. Footnotes Funding: This work was partially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) – Finance Code 001. The funders had no role in the design, conduct or reporting of this study. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-123099). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Data availability free text: Deidentified individual participant data generated during this trial, together with the study protocol and statistical analysis plan, will be made available from six months after publication of the primary study results, upon reasonable request, for a period of one year. Requests should be directed to the corresponding author and will be reviewed by the research team. Data sharing will be subject to institutional approval and, where applicable, approval by the Research Ethics Committee, and will comply with institutional policies and Brazilian data protection legislation. Patient and public involvement: Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details. Data availability statement Data are available upon reasonable request. References Supplementary Materials Data Availability Statement Data are available upon reasonable request.